DEFINITION

An oral selective Janus kinase-1 (JAK1) inhibitor used for moderate-to-severe inflammatory dermatoses, especially atopic dermatitis, by targeting key cytokine signaling pathways.

MECHANISM OF ACTION

Many inflammatory dermatoses, especially atopic dermatitis, are driven by cytokines (such as IL‑4, IL‑13, IL‑31, IFN‑γ, and IL‑6) that signal through the JAK‑STAT pathway.

Under normal conditions, a cytokine binds to its cell surface receptor, activating intracellular Janus kinases (JAKs), which then phosphorylate and activate STAT proteins that travel to the nucleus to turn on inflammatory genes.

Upadacitinib is an oral, small‑molecule inhibitor that selectively blocks JAK1, one of four JAK family members. By inhibiting JAK1, upadacitinib prevents the phosphorylation and activation of STAT proteins downstream of multiple key cytokines.

Specifically, it blocks signaling of IL‑4 and IL‑13 — the central drivers of atopic dermatitis inflammation — as well as IL‑31, a major mediator of itch (pruritus). It also inhibits IFN‑γ and IL‑6, further reducing the broader inflammatory response.

The net result is downregulation of pro‑inflammatory gene transcription, leading to decreased inflammation, reduced pruritus, and improvement of immune dysregulation.

Unlike biologics (e.g., dupilumab) that target only one or two cytokines extracellularly, upadacitinib blocks the intracellular signaling of multiple cytokines simultaneously, which explains its rapid onset of action (often within days).

However, because it broadly suppresses cytokine signaling, it also carries risks such as infections (herpes zoster), thromboembolism, and laboratory abnormalities.

• Selectively inhibits JAK1

• Blocks signaling of multiple cytokines:

  • IL-4, IL-13 → central in atopic dermatitis

  • IL-31 → pruritus mediator

  • IFN-γ, IL-6 → inflammation

Result:

• ↓ inflammation

• ↓ pruritus

• ↓ immune dysregulation

PATHOPHYSIOLOGICAL RATIONALE

• Many inflammatory dermatoses (especially atopic dermatitis) are cytokine-driven via JAK-STAT pathway

• JAK1 inhibition → broad suppression of pro-inflammatory signaling

• Faster onset compared to biologics (exam pearl)

INDICATIONS
(DERMATOLOGY HIGH-YIELD)

Primary:

• Moderate-to-severe atopic dermatitis

Others (less commonly tested but relevant):

• Psoriasis (off-label/less central)

• Alopecia areata (emerging/off-label)

DOSING (EXAM ORIENTED)

• Typically 15 mg or 30 mg once daily (oral)

• Higher dose (30 mg) → greater efficacy but ↑ adverse effects

CLINICAL EFFECTS

• Rapid reduction in:

  • Eczema severity

  • Pruritus (often within days)

• Improves quality of life significantly

ADVERSE EFFECTS (VERY HIGH-YIELD)

Common:

• Acne

• Upper respiratory infections

• Headache

Serious:

1. Infections

• Herpes zoster (important exam point)

• Opportunistic infections

2. Thromboembolic events

• DVT, pulmonary embolism

3. Laboratory abnormalities

• ↑ lipids

• ↑ liver enzymes

• Cytopenias (↓ neutrophils, lymphocytes)

4. Malignancy risk (long-term concern)

5. Major adverse cardiovascular events (MACE)

• Especially in high-risk patients

MONITORING (EXAM-IMPORTANT)

Before starting:

• CBC

• LFTs

• Lipid profile

• Screening for:

  • Tuberculosis

  • Viral hepatitis

During therapy:

• Periodic CBC, LFTs, lipids

CONTRAINDICATIONS / CAUTIONS

• Active serious infection

• History of thromboembolism (relative)

• Severe hepatic impairment

• Pregnancy (avoid)

COMPARISON WITH OTHER THERAPIES

vs Dupilumab

• Upadacitinib:

  • Oral

  • Faster onset

  • Broader immunosuppression

• Dupilumab:

  • Injectable

  • More targeted (IL-4/IL-13)

  • Better safety profile

EXAM-FOCUSED INSIGHTS

• Selective JAK1 inhibitor

• Key drug in moderate-to-severe atopic dermatitis

• Rapid itch relief (important distinguishing feature)

• Risk of herpes zoster and thrombosis

• Requires lab monitoring

MUST-KNOW QUESTIONS

1. A 30-year-old with moderate-to-severe atopic dermatitis fails topical therapy. Which oral JAK inhibitor is FDA-approved for this condition, and what is its primary molecular target?

Answer: Upadacitinib. It selectively inhibits JAK1.

2. A patient on upadacitinib reports almost complete itch relief within 3 days. Inhibition of which two cytokines is most responsible for this rapid antipruritic effect?

Answer: IL-31 (primary pruritus mediator) and IL-4/IL-13.

3. Two weeks after starting upadacitinib 30 mg daily, a patient develops painful unilateral vesicles on the torso. What is the most likely infection, and why is this risk higher with upadacitinib than with dupilumab?

Answer: Herpes zoster (shingles). Upadacitinib causes broader immunosuppression (JAK-STAT pathway inhibition) compared to dupilumab’s targeted IL-4/IL-13 blockade.

4. A 55-year-old with atopic dermatitis and a history of unprovoked deep vein thrombosis asks about upadacitinib. Is this an absolute or relative contraindication, and what two thromboembolic events are associated with this drug?

Answer: Relative contraindication. Associated with DVT and pulmonary embolism.

5. List three baseline laboratory tests required before starting upadacitinib for atopic dermatitis.

Answer: CBC (complete blood count), LFTs (liver function tests), lipid profile. Also screen for tuberculosis and viral hepatitis.

6. A patient on upadacitinib develops fever, cough, and night sweats. What infection screening is mandatory before starting this drug, and which specific opportunistic infection is a class concern?

Answer: Tuberculosis screening (PPD or IGRA). Reactivation of latent TB is a concern, along with herpes zoster.

7. How does the onset of action of upadacitinib compare with dupilumab in atopic dermatitis, and what is the main safety trade-off?

Answer: Upadacitinib has faster onset (days vs. weeks). Trade-off: upadacitinib has broader immunosuppression and higher risks of infection, thromboembolism, and lab abnormalities (lipids, LFTs).

8. A follow-up lipid panel on upadacitinib shows LDL 190 mg/dL and triglycerides 300 mg/dL. Is this a known adverse effect, and what monitoring is recommended?

Answer: Yes, upadacitinib commonly raises lipids. Monitor periodically during therapy; no routine statin initiation unless cardiovascular risk warrants it.

9. A patient with severe hepatic impairment (Child-Pugh C) asks about upadacitinib for atopic dermatitis. Is this safe?

Answer: No. Severe hepatic impairment is a contraindication (avoid use).

10. A 40-year-old on upadacitinib 15 mg daily has inadequate response. What is the maximum dose for atopic dermatitis, and what trade-off should you discuss?

Answer: Increase to 30 mg once daily. Trade-off: greater efficacy but higher risk of adverse effects (infections, acne, lipid elevations, thromboembolism).